SUNITCAP 25 mg contains Sunitinib malate, an oral targeted anticancer medicine. It is a multi-targeted tyrosine kinase inhibitor (TKI) that inhibits receptors involved in tumor growth, angiogenesis, and cancer cell survival, thereby slowing disease progression.

Sunitinib is indicated for treatment of:

1.  Gastrointestinal Stromal Tumor (GIST)
     – After progression or intolerance to imatinib

2.  Advanced / Metastatic Renal Cell Carcinoma (RCC)

3.  Pancreatic Neuroendocrine Tumors (pNETs)
     – Unresectable or metastatic, well-differentiated

Common side effects:

•   Fatigue and weakness

•   Diarrhea

•   Nausea, vomiting

•   Loss of appetite, weight loss

•   Hypertension

•   Hand–foot syndrome

•   Mouth sores

•   Skin and hair color changes

Serious side effects:

•   Cardiac dysfunction (↓ LVEF, heart failure)

•   Severe hypertension

•   Thyroid dysfunction (hypothyroidism)

•   Bleeding or thromboembolic events

•   Liver toxicity

 Regular monitoring of blood pressure, thyroid function, liver function, and cardiac status is essential.

Dosage depends on indication and patient tolerance.

Common regimens:

•   50 mg once daily for 4 weeks ON, 2 weeks OFF (6-week cycle)

•   37.5 mg once daily continuous dosing (commonly in pNETs)

25 mg capsules are commonly used for dose reduction, titration, or combination dosing.


NOTE: This medicine should be taken only under a doctor’s supervision.